Pfizer sweeps out a lineup of neuroscience drugs — as well as cancer and NASH programs — into the scrap heap
Anyone shopping for some early- and mid-stage neurosciences programs should look over the menu of discontinued programs out from Pfizer $PFE this morning.
As the pharma giant already noted, it is getting rid of everything on the neurosciences side except its late-stage pain program allied with Eli Lilly. So the chopping block today includes a Phase I gamma secretes approach, PF-06648671, as well as a GABA-A receptor agonist for epilepsy and a dopamine 1 activator for cognitive disorders.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters